These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20953815)

  • 1. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
    Yamanaka H; Tanaka Y; Inoue E; Hoshi D; Momohara S; Hanami K; Yunoue N; Saito K; Amano K; Kameda H; Takeuchi T
    Mod Rheumatol; 2011 Apr; 21(2):122-33. PubMed ID: 20953815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.
    Takeuchi T; Tanaka Y; Amano K; Hoshi D; Nawata M; Nagasawa H; Sato E; Saito K; Kaneko Y; Fukuyo S; Kurasawa T; Hanami K; Kameda H; Yamanaka H
    Rheumatology (Oxford); 2011 Oct; 50(10):1908-15. PubMed ID: 21752873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2).
    Tanaka Y; Takeuchi T; Inoue E; Saito K; Sekiguchi N; Sato E; Nawata M; Kameda H; Iwata S; Amano K; Yamanaka H
    Mod Rheumatol; 2008; 18(2):146-52. PubMed ID: 18283523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
    Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
    Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
    Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
    Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
    Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
    Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
    Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
    Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
    Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
    Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
    Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
    Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
    Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.